Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dicerna and PBL Sign Agreement for Baulcombe & Hamilton RNAi Patents

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Dicerna Pharmaceuticals, Inc. (Dicerna) and Plant Bioscience Limited (PBL), announced that they have entered an agreement for a non-exclusive licence to PBL’s RNAi intellectual property estate.

PBL will grant Dicerna a world-wide, non-exclusive license to the Baulcombe patents (U.S. Patent Nos. 8,097,710; 8,258,285; 8,299,235 and 8,263,569) for use in the field of human therapeutics.  Financial terms were not disclosed.

“We are pleased to add the Baulcombe patents to our expanding intellectual property portfolio,” said Douglas M. Fambrough, CEO of Dicerna.  “We have continued to innovate and advance our DsiRNA and EnCore technologies, allowing us to develop innovative programs against previously undruggable targets.  Dicerna’s programs, along with those of our partners, means we are moving forward on multiple fronts to bring new options to patients via well-known and powerful mechanisms.”

PBL’s Managing Director, Dr. Jan Chojecki, stated, “We are delighted to add Dicerna as our partner in the development of RNAi therapeutics. Dicerna is currently advancing an exciting RNAi-based therapeutic oncology candidate into the development stage.  This agreement further endorses the strength of our patent estate in the RNAi field and we look forward to working with other partners in therapeutic applications, as well as in research reagents, diagnostics and of course agricultural applications of this pivotal technology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dicerna Reports Progress with GalNAc-DsiRNA-EX-Conjugates
Dicerna has presented preclinical data suggesting the feasibility of its proprietary GalNAc-DsiRNA-EX-Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous (SC) or intravenous (IV) injection.
Thursday, March 03, 2016
Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non-human Primates
The company, a leader in the development of RNA interference (RNAi) therapeutics, presented preclinical data demonstrating the feasibility of its proprietary DsiRNA-EX Conjugate-mediated delivery technology.
Thursday, May 07, 2015
Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer
Mr. Weissman joins Dicerna with more than 25 years in the life sciences industry and will be responsible for corporate development, strategy and other operational functions.
Thursday, January 05, 2012
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!